Precision Medicine and Novel Approaches on Cusp of Breaking Through in Psychiatry

News
1

‘’ The neuropsychiatric space has been gaining traction as “success builds on success,” Butts said, pointing to the recent $14 billion acquisition of Karuna Therapeutics and its schizophrenia asset, KarXT, by Bristol Myers Squibb. BMS is already seeing a return on its investment as Phase III in April showed significant and sustained symptom improvement in patients taking KarXT.

If approved, KarXT would be the first new class of medicine for schizophrenia in over 50 years, Karuna founder and Chief Operating Officer Andrew Miller [told] BioSpace in a previous interview. The M1/M4-preferring muscarinic agonist is being reviewed by the FDA with an action date of September 26.

Another recent deal in the schizophrenia space came last December, when AbbVie [dropped] $8.7 billion to acquire Cerevel Therapeutics, picking up its late-stage, next-generation antipsychotic emraclidine. The asset is a positive allosteric modulator of the muscarinic M4 receptor being tested in schizophrenia and Alzheimer’s disease psychosis.

“Those kinds of [deals] help the rest of our industry,” Butts said.‘’

5 Likes
2

Lol his name is Butts

3 Likes
3

Emraclidine is in phase 3?

And, does this med also work differently like KARXT?

1 Like
4

Apparently we’re worth billions.

2 Likes
5

Emraclidine targets the muscarinic acetylcholine 4 receptor subtype (M4). And KarXT targets M4 and M1 receptors.

1 Like
6

Been hearing this kind of thing for over three decades. Still waiting for the miracle to move beyond the press release and into a real treatment.

1 Like
7

The era of precision psychiatry began in these years. We are going to have to wait a decade or two perhaps to see ‘‘definitive’’ treatments. At least that’s my opinion.